Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Scheer, Justin M ^a   Sandoval, Wendy ^a   Elliott, J Michael ^a   Shao, Lily ^a   Luis, Elizabeth ^a   Lewin Koh, Sock Cheng ^a   Schaefer, Gabriele ^a   Vandlen, Richard ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ISOMER; PEPTIDE MAPPING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN FAB FRAGMENTS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 84871457674     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051817     Document Type: Article

References (33)

1. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnology 26: 925-932.
2. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, et al. (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clinical Cancer Research 16: 4769-4778.
3. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, et al. (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114: 2721-2729.
4. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, et al. (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods 332: 41-52.
5. Wieduwilt MJ, Moasser MM, (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65: 1566-1584.
6. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
7. Kruser TJ, Wheeler DL, (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316: 1083-1100.
8. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, et al. (1992) High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology (N Y) 10: 163-167.
9. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, et al. (2002) Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 263: 133-147.
10. Montgomery DC (2001) Design and Analysis of Experiments. New York: John Wiley and Sons, Inc.
11. Littell RC, Milliken GA, Stroup WW, Wolfinger RD (2006) SAS for Mixed Models. Cary: SAS Institute, Inc.
12. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, et al. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887.
13. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
14. Chames P, Baty D, (2009) Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 12: 276-283.
15. Kontermann RE, (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26: 1-9.
16. Carter P, Fendly BM, Lewis GD, Sliwkowski MX, (2000) Development of herceptin. Breast Dis 11: 103-111.
17. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, et al. (2005) 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104: 2701-2708.
18. Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, et al. (2009) Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. International Journal of Oncology 34: 25-32.
19. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG, (2004) Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601-2609.
20. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
21. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, et al. (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317-328.
22. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
23. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J, (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
24. Kirkpatrick DS, Gerber SA, Gygi SP, (2005) The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 35: 265-273.
25. Liu YD, Chen X, Enk JZ, Plant M, Dillon TM, et al. (2008) Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 283: 29266-29272.
26. Smigel MD, Lazar JD, (1981) Improved fitting of radioimmunoassay data by Scatchard analysis. Int J Biomed Comput 12: 189-203.
27. Jura N, Endres NF, Engel K, Deindl S, Das R, et al. (2009) Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137: 1293-1307.
28. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J, (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A 106: 21608-21613.
29. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, et al. (2009) The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 34: 641-651.
30. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, et al. (1991) Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proceedings of the National Academy of Sciences of the United States of America 88: 8691-8695.
31. Yip YL, Novotny J, Edwards M, Ward RL, (2003) Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling. International Journal of Cancer 104: 303-309.
32. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, et al. (2011) Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. Cancer Research 71: 1871-1882.
33. Horgan C, Brown K, Pincus SH, (1993) Studies on antigen binding by intact and hinge-deleted chimeric antibodies. J Immunol 150: 5400-5407.